System and methods to enhance chemotherapy delivery and reduce toxicity
AssigneeSigyn Therapeutics, Inc.
InventorJames A. Joyce
Life of this patent
Estimating the term…
Abstract
Despite therapeutic advances in the field of oncology, treatment toxicity, drug resistance, and inadequate tumor site delivery restrict the benefit of cancer chemotherapy regimens. Disclosed are extracorporeal devices comprising adsorbent components that are suitable for treating a subject prior to and following administration of a dose of a chemotherapy drug, wherein the devices are configured to remove circulating factors comprising a chemotherapy drug from blood or plasma. Also disclosed herein are methods of reducing the bloodstream presence of circulating factors that mediate drug resistance, drug toxicity, and cancer metastasis, wherein circulating factors include without limitation, tumor-derived and/or chemotherapy-induced extracellular vesicles or exosomes.
Claims28
A method for improving the safety and efficacy of a chemotherapy drug in a subject in need thereof, comprising:
- a) introducing blood or plasma from a subject into a first extracorporeal device comprising an adsorbent, wherein the blood or plasma comprises an amount of a pre-chemotherapy target molecule or compound, and wherein said pre-chemotherapy target molecule or compound is induced by a tumor;
- b) contacting the blood or plasma with the adsorbent in the first extracorporeal device to allow the pre-chemotherapy target molecule or compound to bind to the adsorbent;
- c) reintroducing the blood or plasma into the subject, wherein the blood or plasma obtained after (b) has a reduced amount of the pre-chemotherapy target molecule or compound as compared to the blood or plasma of the subject prior to (b);
- d) administering a chemotherapy drug to the subject;
- e) introducing blood or plasma from the subject into a second extracorporeal device comprising a second adsorbent, wherein the blood or plasma comprises an amount of a post-chemotherapy target molecule or compound,
- f) contacting the blood or plasma with the second adsorbent in the second extracorporeal device to allow the post-chemotherapy target molecule or compound present in blood or plasma to bind to the adsorbent;
- and
- g) reintroducing the blood or plasma into the subject, wherein the blood or plasma obtained after (f) is measured to have a reduced amount of the post-chemotherapy target molecule or compound as compared to the blood or plasma of the subject prior to (f).
A method for improving the safety and efficacy of a chemotherapy drug in a subject in need thereof prior to administration of a chemotherapeutic agent, comprising:
- a) providing a pre-chemotherapy extracorporeal device comprising an adsorbent;
- b) introducing blood or plasma from a subject into said extracorporeal device, wherein the blood or plasma comprises an amount of a target molecule or compound, and wherein said target molecule or compound is induced by a tumor;
- c) contacting the blood or plasma with the adsorbent in the extracorporeal device to allow the target molecule or compound to bind to the adsorbent;
- d) reintroducing the blood or plasma into the subject, wherein the blood or plasma obtained after (c) has a reduced amount of the target molecule or compound as compared to the blood or plasma of the subject prior to (c);
- and
- e) administering a chemotherapy drug to the subject.
A method for improving the safety and efficacy of a chemotherapy drug in a subject in need thereof after a chemotherapeutic has been administered, comprising:
- a) introducing blood or plasma from the subject into an extracorporeal device comprising an adsorbent, wherein the blood or plasma comprises an amount of the target molecule or compound,
- b) contacting the blood or plasma with the adsorbent in the extracorporeal device to allow the target molecule or compound present in blood or plasma to bind to the adsorbent;
- and
- c) reintroducing the blood or plasma into the subject, wherein the blood or plasma obtained after (b) is measured to have a reduced amount of the target molecule or compound as compared to the blood or plasma of the subject prior to (b);
- wherein the extracorporeal device is configured to capture circulating target molecules or compounds from blood or plasma after chemotherapy treatment is concluded.
Dependencies are inferred from the claim text.